ISO 13485 and the Essential Principles: Which Standards Bangladesh Adopts

1. Key takeaways

Bangladesh sets out its standards framework in §7.1 of the DGDA medical device registration guideline. To demonstrate conformity with the relevant regulatory requirements, DGDA adopts ISO 13485 and the Essential Principles of Safety and Performance of medical devices. Separately, §4.2 provides that a manufacturer following current ISO or IEC standards, other official standards, or standards validated by the manufacturer itself is presumed to conform to the essential requirements.

The two provisions do different work, and the difference is often lost in reading. Section 7.1 names the instruments DGDA has adopted. Section 4.2 supplies a presumption of conformity and, unusually, extends it to standards the manufacturer has validated in the absence of an official one. That second limb is the part most applicants never use.

• Two instruments: ISO 13485 and the Essential Principles, adopted under §7.1.
• Presumption route: conformity with ISO, IEC, other official standards, or the manufacturer’s own validated standards, under §4.2.
• Certification layer: notified body QMS certification for Class B, C and D, with design certification added for Class D under §4.6.
• Parallel obligations: the quality system requirement and the product requirement are separate and both must be evidenced.
• Labelling standards: GHTF/SG1/N70:2011 and ISO 15223-1:2007 are cited by number under §7.2, unlike the standards in §7.1.

2. Legal basis

The framework is compact enough to be read in one sitting, which makes its internal inconsistencies more visible. Section 7.1 adopts ISO 13485 and the Essential Principles and adds that harmonised standards include United States Pharmacopeia and European Pharmacopoeia monographs for certain product families. Section 4.2 provides the presumption of conformity. Section 4.6 sets the certification level by class, and section 4.7 requires existing foreign certification to be filed. Section 7.2 governs labelling and does so by citing specific editions.

No provision in this set defines the Essential Principles in a Bangladeshi annex. The term is used as a term of art, and the practical reading is that the internationally recognised set of essential principles is what DGDA has in mind. Applicants should therefore be explicit about which edition they are mapping against, since the guideline does not say.

3. Expert insights

Insight 1: the manufacturer-validated standard route in §4.2 is underestimated. Most markets require conformity with harmonised standards or with national standards, and stop there. Bangladesh adds the manufacturer’s own validated standards, on condition that they have in fact been validated. For innovative devices, and for products with no settled standard to point to, the value of this is considerable: there is no need to wait for an international standard to be published before the conformity argument can be made. What the route demands in exchange is validation evidence, meaning the method, the acceptance criteria and the results that justify treating the internal standard as a sound basis for the presumption. In practice few applicants use the route because few arrive with that evidence prepared.

Insight 2: the standards cited in §7.1 are not version-locked, while those in §7.2 are. Section 7.1 refers to ISO 13485 and the Essential Principles without naming an edition. Section 7.2, by contrast, pins GHTF/SG1/N70:2011 and ISO 15223-1:2007 precisely. Both pinned references have aged: the GHTF concluded its work in 2012 and its functions passed to the IMDRF, and ISO 15223-1 has since been revised. This suggests that labels can be produced to the current ISO 15223-1, provided the dossier carries an explanation of the version the guideline cites, so that the difference is visible and reasoned rather than appearing as an oversight. The alternative, printing to a withdrawn edition, creates a different and less defensible problem.

Insight 3: the Essential Principles and ISO 13485 are two parallel requirements, not one. ISO 13485 governs the quality management system; the Essential Principles govern the safety and performance of the product. A certified quality system is evidence that the manufacturer can make the device consistently; it is not evidence that the device is safe and performs as intended. In practice companies often submit an ISO 13485 certificate and consider the conformity question answered, which leaves the product-level evidence missing. Two documents, and neither substitutes for the other.

Insight 4: §4.7 turns existing approvals into evidence rather than into a shortcut. Foreign NRA and notified body certificates and foreign marketing approvals must be submitted for DGDA to consider. They inform the review; they do not displace it. The useful consequence is that a well-maintained certificate portfolio reduces the questions a reviewer needs to ask about the quality system.

4. Practical recommendations

At dossier preparation GRZAN produces an Essential Principles compliance matrix. Each principle is listed line by line and mapped to specific evidence: the standard number relied on, the test report number, and the section of the risk management file where the item is addressed. In our experience this matrix is the single most useful document at technical review, because it turns evidence scattered across dozens of files into one continuous line that a reviewer can follow. We also require clients to produce label symbols to the current edition of ISO 15223-1 and to attach a symbol explanation page to the dossier, which removes the questions that a version difference would otherwise raise.

• Build the matrix before writing the summary. Principle, evidence, report number, file section, in that order.
• Decide the standards route product by product. Harmonised standard where one exists, validated internal standard where none does, with the validation record attached.
• Name the edition. State which edition of the Essential Principles and which edition of each standard is being applied.
• Keep the quality system evidence and the product evidence separate. A certificate answers the first question only.
• Explain version differences on the page. A short note on the symbol page resolves what would otherwise become a deficiency.

5. Verification checklist

• □ ISO 13485 certificate prepared, issued by a notified body for Class B, C and D
• □ Essential Principles compliance matrix prepared, with evidence mapped principle by principle
• □ For products without a settled standard, validation records for the manufacturer-validated standard prepared under §4.2
• □ Pharmacopoeial monograph applicability checked for drug-device combinations, sutures and bandages
• □ Label symbols produced to the current ISO 15223-1, with a symbol explanation page attached
• □ EC design examination certificate attached separately for Class D

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com